EUVIMEDEUVIMED entdecken
Crossref

A Platform for the Production of Pleuromutilin and Core-Modified Derivatives

Zhanhao Liang iD, Qimin Yang, Antonio Ramkissoon, Carolyn M Shoen iD, Michael Cynamon, Seth B Herzon iD

Journal of the American Chemical Society · 2026

DOI: 10.1021/jacs.6c13738 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Chemical Society, 2026. Verfasst von Zhanhao Liang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Yale University, New Haven, Connecticut06520, United States. Hauptthemen laut MEDLINE: Diterpenes, Anti-Bacterial Agents. Die Arbeit nennt 67 Literaturangaben. Gefördert von: National Institutes of Health (NIH).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The structural complexity of pleuromutilin antibiotics has limited efforts to define aspects of the natural scaffold that are required for antibacterial activity. Here, we present a scalable synthetic platform that provides access to novel core-modified bicyclic pleuromutilins (BPs) and the natural tricyclic pleuromutilin skeleton from a common β-ketoester precursor. Structurally, BPs lack the cyclopentanone ring, C10, and C11 substituents, while retaining the 6/8 boat–chair framework, C22 extension, and C12 diversification vector. This approach proceeds through an advanced bis(sulfonate) intermediate, which can be prepared in 10 steps on a multigram scale. Diversification through a single-flask, 2-fold substitution then furnished >30 analogs. Among the analogs prepared, C12 carbamate derivatives possessed the most potent antibacterial activity, with selected analogs showing Gram-positive activity comparable to tiamulin and measurable activity against the Gram-negative pathogen Acinetobacter baumannii. Additionally, one analog had promising activity against cfr+Staphylococcus aureus, a clinically relevant pathogen that is resistant to ribosome-targeting antibiotics, including pleuromutilin itself. Additional derivatives showed activity against mycobacteria Mycobacterium avium and M. bovis. The route was further developed to enable new syntheses of (+)-mutilin and (+)-pleuromutilin. This platform enables synthesis-driven exploration of both minimal and fully elaborated pleuromutilin architectures.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DiterpenesAnti-Bacterial AgentsPleuromutilinsPolycyclic CompoundsMicrobial Sensitivity TestsMolecular Structure

Substanzen

PleuromutilinsDiterpenesAnti-Bacterial AgentsPolycyclic Compounds

Autor:innen und Institutionen

  • Department of Chemistry, Yale University, New Haven, Connecticut06520, United States.
  • Department of Chemistry and Chemical Biology, Harvard University, Cambridge, Massachusetts02138, United States.
  • Veterans Affairs Medical Center, 800 Irving Avenue, Syracuse, New York13210, United States.
  • Departments of Pharmacology and Therapeutic Radiology, Yale School of Medicine, New Haven, Connecticut06520, United States.

ORCID-Profile: Zhanhao Liang, Carolyn M Shoen, Seth B Herzon

Förderung

  • National Institutes of Health (NIH)

Zitieren

APA

Liang, Z., Yang, Q., Ramkissoon, A., Shoen, C. M., Cynamon, M., & Herzon, S. B. (2026). A Platform for the Production of Pleuromutilin and Core-Modified Derivatives. Journal of the American Chemical Society. https://doi.org/10.1021/jacs.6c13738

Vancouver

Liang Z, Yang Q, Ramkissoon A, Shoen CM, Cynamon M, Herzon SB. A Platform for the Production of Pleuromutilin and Core-Modified Derivatives. Journal of the American Chemical Society. 2026. doi:10.1021/jacs.6c13738

BibTeX
@article{Liang2026,
  author = {Liang, Zhanhao and Yang, Qimin and Ramkissoon, Antonio and Shoen, Carolyn M and Cynamon, Michael and Herzon, Seth B},
  title = {A Platform for the Production of Pleuromutilin and Core-Modified Derivatives},
  journal = {Journal of the American Chemical Society},
  year = {2026},
  doi = {10.1021/jacs.6c13738}
}
Kostenlos starten →